Literature DB >> 27073510

Radiation-induced low-grade fibromyxoid sarcoma of the chest wall nine years subsequent to radiotherapy for breast carcinoma: A case report.

Shino Shibata1, Kenshiro Shiraishi2, Hideomi Yamashita2, Reiko Kobayashi2, Keiichi Nakagawa2.   

Abstract

The present study reports a case of low-grade fibromyxoid sarcoma that occurred in a 62-year-old woman 9 years subsequent to whole breast irradiation for a carcinoma of the left breast, and 18 years following chemotherapy and radiotherapy (RT) for non-Hodgkin's lymphoma (NHL; diagnosed at the age of 43). The patient was 53 years of age when a cT2N0M0 stage IIA breast tumor was identified and excised. A 2.5 cm diameter nodule with dimpling in the upper-outer region of the left breast was detected. Pathological examination revealed that the tumor was an invasive ductal carcinoma, of a solid tubular type. The patient was treated with post-surgical whole breast RT. The left breast received 46 Gy in 23 fractions (2 Gy per fraction) for 4 weeks and 3 days, followed by a cone down boost of 14 Gy in 7 fractions (2 Gy per fraction); therefore a total dose of 60 Gy in 30 fractions was administered. In total, 9 years subsequent to RT, the patient observed a small lump in the left chest wall. The patient underwent excision of the tumor and pectoralis major fascia. Microscopically, the tumor consisted of atypical spindle cells with myxoid stroma. Pathologists concluded that the tumor was a low-grade fibromyxoid sarcoma. Since the tumor developed from tissue in a previously irradiated region, it was considered to be RT-induced, and was classified using the radiation-induced sarcoma (RIS) criteria as dictated by Cahan. Although the majority of RIS cases are angiosarcomas, a rare, low-grade fibromyxoid sarcoma was observed in the present study. The present study hypothesizes that there may have been an overlap region between the RT for supraclavicular nodes of NHL and the whole breast RT for primary breast cancer, due to the results of a retrospective dose reconstruction undertaken by the present study. The patient remained clinically stable for 4 years thereafter, until 2008 when the patient experienced a local relapse and underwent surgery. On 19 October 2011, the patient succumbed to RIS. The current study suggests that the RT history of a patient requires consideration due to the possible development of RIS, including the development of a low-grade fibromyxoid sarcoma, which may lead to a poor prognosis.

Entities:  

Keywords:  Evans tumor; low-grade fibromyxoid sarcoma; radiation-induced sarcoma; whole breast irradiation

Year:  2016        PMID: 27073510      PMCID: PMC4812097          DOI: 10.3892/ol.2016.4221

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Sarcoma arising in irradiated bone: report of eleven cases. 1948.

Authors:  W G Cahan; H Q Woodard; N L Higinbotham; F W Stewart; B L Coley
Journal:  Cancer       Date:  1998-01-01       Impact factor: 6.860

Review 2.  Angiosarcoma after breast-conserving therapy.

Authors:  Alan T Monroe; Steven J Feigenberg; Nancy Price Mendenhall
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

3.  Soft tissue sarcoma after treatment for breast cancer--a Swedish population-based study.

Authors:  P Karlsson; E Holmberg; A Samuelsson; K A Johansson; A Wallgren
Journal:  Eur J Cancer       Date:  1998-12       Impact factor: 9.162

Review 4.  Epithelioid leiomyosarcoma of the uterine cervix: a case report and review of the literature.

Authors:  Masafumi Toyoshima; Chikako Okamura; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi
Journal:  Gynecol Oncol       Date:  2005-06       Impact factor: 5.482

5.  Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer.

Authors:  Sharon Galper; Rebecca Gelman; Abram Recht; Barbara Silver; Anita Kohli; Julia S Wong; Teresa Van Buren; Elizabeth H Baldini; Jay R Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

6.  Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment.

Authors:  Carole Rubino; Akthar Shamsaldin; Monique G Lê; Martine Labbé; Jean-Marc Guinebretière; Jean Chavaudra; Florent de Vathaire
Journal:  Breast Cancer Res Treat       Date:  2005-02       Impact factor: 4.872

7.  Long-term complications associated with breast-conservation surgery and radiotherapy.

Authors:  Funda Meric; Thomas A Buchholz; Nadeem Q Mirza; Georges Vlastos; Frederick C Ames; Merrick I Ross; Raphael E Pollock; S Eva Singletary; Barry W Feig; Henry M Kuerer; Lisa A Newman; George H Perkins; Eric A Strom; Marsha D McNeese; Gabriel N Hortobagyi; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2002-07       Impact factor: 5.344

8.  Why do patients with radiation-induced sarcomas have a poor sarcoma-related survival?

Authors:  B Bjerkehagen; M C Småstuen; K S Hall; S Skjeldal; S Smeland; S D Fosså
Journal:  Br J Cancer       Date:  2011-12-15       Impact factor: 7.640

Review 9.  Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Authors:  S Darby; P McGale; C Correa; C Taylor; R Arriagada; M Clarke; D Cutter; C Davies; M Ewertz; J Godwin; R Gray; L Pierce; T Whelan; Y Wang; R Peto
Journal:  Lancet       Date:  2011-10-19       Impact factor: 79.321

Review 10.  Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature.

Authors:  C Adem; C Reynolds; J N Ingle; A G Nascimento
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more
  1 in total

1.  Low-grade Fibromyxoid Sarcoma: Treatment Outcomes and Efficacy of Chemotherapy.

Authors:  Florence Chamberlain; Bodil Engelmann; Omar Al-Muderis; Christina Messiou; Khin Thway; Aisha Miah; Shane Zaidi; Anastasia Constantinidou; Charlotte Benson; Spyridon Gennatas; Robin L Jones
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.